AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
![GlobeNewswire](../../../Content/images/providers/GN.png)
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: GlobeNewswire
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapyACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunotherapy in Parkinson’s disease (PD) on track for safety and immunogenicity interim data in H2 2024Three-year cash runway with CHF 104.8 million at quarter end, plus $100 million upfront from Takeda and the anticipated ACI-35.030-related CHF 25 million milestone Lausanne, Switzerland, May 13, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative di
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- Takeda Signs Option to Market Ascentage's Blood-Cancer Drug [BNN Bloomberg (Canada)]BNN Bloomberg
- Here's Why Shareholders May Want To Be Cautious With Increasing AC Immune SA's (NASDAQ:ACIU) CEO Pay Packet [Yahoo! Finance]Yahoo! Finance
- Blood Brain Barrier Market Untapped Growth Opportunities Analysis - Latest Report by InsightAce Analytic Pvt. Ltd. [Yahoo! Finance]Yahoo! Finance
- AC Immune SA (NASDAQ:ACIU): Are Analysts Optimistic? [Yahoo! Finance]Yahoo! Finance
- AC Immune SA (NASDAQ: ACIU) is now covered by analysts at BTIG Research. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
ACIU
Earnings
- 5/13/24 - Miss
ACIU
Sec Filings
- 5/21/24 - Form 6-K
- 5/16/24 - Form 144
- 5/13/24 - Form 6-K
- ACIU's page on the SEC website